Immutep And Dr. Reddy's Enters Into Strategic Collaboration For Commercialisation Of An Innovative Oncology Drug, Eftilagimod Alfa

Reuters
Dec 08, 2025
Dec 8 (Reuters) - Immutep Ltd ::
*IMMUTEP AND DR. REDDY’S ENTERS INTO STRATEGIC COLLABORATION FOR COMMERCIALISATION OF AN INNOVATIVE ONCOLOGY DRUG, EFTILAGIMOD ALFA
*IMMUTEP LTD - TO RECEIVE USD 20 MILLION UPFRONT AND UP TO USD 349.5 MILLION
*IMMUTEP LTD - DR. REDDY'S RECEIVES EXCLUSIVE RIGHTS FOR EFTILAGIMOD ALFA IN ALL COUNTRIES OUTSIDE NORTH AMERICA, EUROPE, JAPAN, & GREATER CHINA

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 08-DEC-202513:00:01.217 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10